Interaction of synthetic opioid metenkephalin peptide analogs, lilly 127623 and FK 33-824 with indole hallucinogens: Antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat by Domino, Edward F. & Ruffing, Diane M.
Psychopharmacology (1983) 80: 3 t 5 -  318 
Psychopharmacology 
9 Springer-Verlag 1983 
Interaction of Synthetic Opioid Metenkephalin Peptide Analogs, 
Lilly 127623 and FK 33-824 with Indole Hallucinogens: 
Antagonism of N,N-Dimethyltryptamine- and LSD-Induced Disruption 
of Food-Rewarded Bar Pressing Behavior in the Rat 
Diane M. Ruffing 1 and Edward F. Domino 2 
1 Division of Pharmacology, Lafayette Clinic, 951 E. Lafayette, Detroit, MI 48207, USA 
2 University of Michigan, Department of Pharmacology, Ann Arbor, MI 48109, USA 
Abstract. The selected opioid metenkephalin synthetic pep- 
tide analogs Lilly (LY) 127623 and FK 33-824 were tested for 
behavioral dose effects and potential interaction with N,N- 
dimethyltryptamine (DMT) and lysergic acid diethylamide- 
25 (LSD) in adult male Holtzman rats trained on a positive 
reinforcement fixed-ratio 4 (FR-4) behavioral bar pressing 
schedule, i.e., a reward of'0.01 ml sugar-sweetened evap- 
orated milk was earned on every fourth bar press. DMT 
(3.2 mg/kg) and LSD (0.1 mg/kg), administered IP following 
a 0.9% NaC1 15-20-min control pretreatment, disrupted 
established food-rewarded FR-4 bar pressing in a consistent 
and reproducible manner. Animals pretreated IP with prede- 
termined behaviorally noneffective doses of LY 127623 
(0.01 - 0.32 mg/kg) and FK 33-824 (0.001 - 0.01 mg/kg) 1 5 -  
20 min prior to receiving DMT demonstrated significant 
antagonism to DMT-induced disruption of FR-4 bar press- 
ing, while doses of 0 .10-0 .32mg/kg LY 127623 and 
0.00032- 0.0032 mg/kg FK 33-824 significantly antagonized 
LSD-induced behavioral effects. 
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Operant behavior 
A therapeutic or pathogenic involvement of opioids in 
psychoses has been indicated by numerous biological and 
pharmacological investigations (Barchas et al. 1980; van 
Praag and Verhoeven 1980; deWied 1980; Marx 1981; 
Anokhina 1982). These studies, coupled with the recent 
evidence of multiple opiate receptors and endogenous opioid- 
like peptides, have stimulated interest in the potential be- 
havioral and therapeutic applications of endogenous endor- 
phins, enkephalins, and their related synthetic analogs 
(Gesellchen and Zimmermann 1981 ; Martin 1981 ; Van Ree 
and deWied 1981; Szara 1982). 
In recent investigations we reported that the opioid 
antagonists naloxone and naltrexone potentiated induced 
disruptive effects of N,N-dimethyltryptamine (DMT) and 
LSD on food-rewarded fixed-ratio (FR-4) behavior in the rat, 
whereas low doses of the opioid agonists morphine and 
methadone antagonized the behavioral effects of DMT and 
LSD, while larger doses selectively potentiated only the 
effects of LSD (Ruffing and Domino 1979, 1981). The 
purpose of the present study was to determine possible 
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interactions of selected metenkephalin synthetic peptide ana- 
logs with DMT and LSD using rodents in an operant FR-4 
behavioral paradigm. 
Materials and Methods 
Adult male Holtzman rats (at least 90 days of age) were 
housed separately in a constant temperature- and humidity- 
controlled environment. Animals were maintained at approx- 
imately 70 % of their expected free-feeding weight. 
Procedures. The methods for establishing stable food- 
rewarded FR-4 bar pressing and experimental design param- 
eters have been described in detail (Ruffing and Domino 
1981). In brief, rats were trained to bar press daily for sessions 
of 60-rain duration on a FR schedule to receive a reward of 
0.01 ml sweetened evaporated milk solution as positive 
reinforcement on every fourth bar press. Operant behavioral 
experiments were performed in an isolated, darkened room 
using Lehigh Valley Electronics rodent operant test chambers 
(model 143-21) and Gerbrand cumulative recorders. 
Subsequent to established, stable FR-4 bar pressing, rats 
were randomly scheduled to assigned drug and dose groups 
(N = 6 - 1 2 )  and daily bar pressing sessions of 60-rain 
duration for at least 5 days prior to injections. Each animal 
served as its own control to compare hallucinogen-induced 
effects with and without assigned pretreatment drugs, with an 
intervening minimum 7-day drug-free interval between sched- 
uled injections. Prior to the assigned hallucinogen injection 
(3.2 mg/kg DMT or 0.1 mg/kg LSD IP), control groups were 
pretreated (15 - 2 0  rain) with 0.9 % NaC1 (IP), whereas drug- 
pretreated groups received a predetermined behaviorally 
noneffective dose of LY 127623 (0.0032-0.32 mg/kg IP) or 
FK 33-824 (0.0001-0.01 mg/kg IP) as pretreatment 1 5 -  
20 rain prior to DMT or LSD. The pretreatment drug doses 
described demonstrated no effect on bar pressing for 120-rain 
periods, as predetermined in pilot studies (Domino and 
Ruffing 1982). Drugs were administered IP and dosages refer 
to free base content. 
Data Analysis. The duration of drug effect was determined 
from the length of the horizontal line generated by the 
cumulative recorder illustrating the onset, duration, and 
cessation of drug effects or disruption of bar pressing 
behavior. Two-tailed Student's t-test paired comparisons, 
calculated according to Snedecor and Cochran (1967), were 
used to analyze the statistical significance of drug effects for 
control and corresponding drug-pretreated groups, i.e., antag- 
onism, potentiation, or no effect on the behavioral FR-4 
316 
disruptive effects characteristically induced by DMT and 
LSD. 
Drugs. DMT was obtained from Sigma (St. Louis, MO, USA) 
and solutions were prepared by dissolving the free base in 1 N 
HC1, adding 0.9 % NaCI, and titrating the acidity with 0.1 N 
N a O H  to adjust pH to 4 .5-5 .0 .  LSD-25 (Delysid) was 
obtained from the National Institute on Drug Abuse and was 
administered in 0.9 % NaCI. Lilly (LY) 127623 (Metkeph- 
amid) and F K  33-824 log doses were administered in 0.9 % 
NaCI, and supplied courtesy of  Dr. R. Frederickson (Lilly 
Research Laboratories, Eli Lilly and Company, Indianapolis, 
IN, USA) and Drs. Graffenried and del Pozo (Department of 
Experimental Therapeutics, Biololgical and Medical 
Research Division, Sandoz Limited, Basel, Switzerland), 
respectively. 
Results  
Characteristic gross behavioral effects of DMT  and LSD 
were evident 2 - 5  rain following IP injections and consisted 
of  lying quietly with eyes open in an excessively flattened 
position for prolonged intervals, periodic display of Straub 
tail with or without locomotor or body movements, circling 
or reverse crawling in a flattened position, splayed legs or 
extension of  the hind limbs, frequent stere9 and re- 
petitive head or body movements, sustained periods of 
arching, and disinterest in food or bar pressing. The gross 
behavioral effects of DMT (3.2 mg/kg) and LSD (0.1 mg/kg) 
were reproducible and commensurable with the duration of  
induced disruption of  food-rewarded FR-4 bar pressing 
behavior. 
In the LY 127623 and FK 33-824 pretreatment groups, 
gross behavioral effects following DMT or LSD were usually 
minimal or absent, although atypical gross behavioral effects 
were noted in several animals (N = 4), i.e., mild to moderate 
increase in behavioral locomotor activity involving excessive 
exploring, grooming, and periodic interest in the bar, which 
may or may not have resulted in pressing ffor food reinforce- 
ment. Following the cessation of  drug effects, rats would 
appear normal, groom briefly, and abruptly start and con- 
tinue bar pressing at preinjection response rates. Typically, 
cumulative bar pressing records of  rats trained on food- 
rewarded FR-4 schedules show constant high rates of re- 
sponse with momentary postreinforcement pausing (Ferster 
and Skinner 1957; Wenger 1980). 
The synthetic metenkephalin peptide pretreatment groups 
showed that some doses of  LY 127623 (0 .01-0 .32 mg/kg) 
and FK 33-824 (0.00032-0.01 mg/kg) significantly antago- 
nized the disruption of  FR-4 bar pressing induced by DMT 
and LSD. As illustrated in Fig. 1, pretreatment doses of  LY 
127623 (0.01 - 0 . 3 2  mg/kg) and FK 33-824 (0.001-0.01 rag/ 
kg) significantly antagonized DMT-induced disruption of  
FR-4 bar pressing, while significant antagonism to the LSD- 
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Fig. 1. Dose-dependent effects of Lilly 127623 and FK 33-824 pretreatment on the duration of DMT- and LSD-induccd disruption of food-rewarded 
FR-4 bar pressing in the rat. In control and drug-pretreatment bar pressing sessions, designated groups (N = 6 - 12) received fixed doses of DMT 
(3.2 mg/kg) or LSD (0.1 mg/kg) with each rat serving as its own control. Graph points represent the mean duration (min + SE) of FR-4 bar pressing 
disruption, with solid lines (9 9 representing control groups and broken lines (e . . . .  o )  representing corresponding Lilly 127623 (0.0032- 
0.32 mg/kg) and FK 33-824 (0.0001-0.01 mg/kg) pretreatment groups. For control pretreatment, groups received 0.9 % NaCI 15 -20 rain prior to 
DMT or LSD. In drug-pretreated groups predetermined behaviorally noneffective doses of LY 127623 and FK 33-824 were also administered at 15 - 
20 rain intervals prior to DMT or LSD. Significant antagonism to DMT-induced disruption of FR-4 bar pressing is shown with pretreatment doses of 
LY 127623 (0.01-0.32 mg/kg) and FK 33-824 (0.001-0.01 mg/kg) (top), whereas antagonism of-LSD-induced behavioral effects is shown with LY 
127623 (0.10-0.32 mg/kg) and FK 33-824 (0.00032-0.0032 mg/kg) pretreatment (bottom). Statistical significance of drug effects for control and 
corresponding pretreatment groups were calculated using two-tailed paired-comparison Student's t-tests in which the following symbols apply: 
* P < 0.05; **P < 0.01 ; ***P < 0.001. Numbers enclosed by parentheses represent the number of animals in designated groups. All injections were 
administered IP 
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induced behavioral effects is shown with doses of LY 127623 
(0.10-0.32 mg/kg) and FK 33-824 (0.00032-0.0032 rag/ 
kg). Although no differences from the DMT-induced effect 
were observed with pretreatment doses of 0.0032 mg/kg LY 
127623 or 0.00032 mg/kg FK 33-824, and no differences from 
the LSD-induced effect were observed with 0.032 mg/kg LY 
127623 or 0.0001 mg/kg and 0.01 mg/kg FK 33-824, it should 
be noted that typical gross behavioral effects characteristi- 
cally observed with DMT or LSD were minimal or absent for 
the duration of induced disruption of FR-4 bar pressing. The 
data indicate LY 127623 as the more effective antagonist for 
DMT (3.2 mg/kg) and FK 33-824 as the more effective LSD 
(0.1 mg/kg) antagonist. 
Discussion 
The present study demonstrates complex interactions be- 
tween the synthetic metenkephalin opioid peptide analogs LY 
127623 and FK 33-824 and the indole hallucinogens DMT 
and LSD. The dramatic antagonistic dose-dependent effects 
of the opioid peptides reported parallel the previous findings 
that the opioid agonists morphine and methadone antago- 
nized disruption of FR-4 bar pressing induced by DMT and 
LSD, whereas the opioid antagonists naloxone and nal- 
trexone potentiated the effects of DMT and LSD (Ruffing 
and Domino 1979, 1981). 
Evidence implicating endogenous ligands and opioid re- 
ceptors in the pathogenesis of various psychiatric illnesses has 
been reported by numerous investigators (Usdin et al. 1979; 
Olson et al. 1981 ; Gacel et al. 1981). As a model for psychosis, 
DMT and LSD-25 were used because they induce and mimic 
various aspects of psychotic behavior (Stoff et al. 1978; 
Jenner et al. 1980; Shulgin 1981). While DMT has been 
identified as an endogenous substance (Smythies et al. 1979), 
which can be synthesized from tryptamine in various tissues 
of humans and animals (Saavedra et al. 1973), significant 
differences in the amount of DMT excreted by psychotic and 
normal individuals have also been demonstrated (Erdelyi et 
al. 1979; Murray et al. 1979). Similarly, LSD-displacing 
factors (LDF) have been reported in unmedicated psychotic 
patients (Mehl et al. 1977) while, in rat brain endogenous 
ligands for two distinct LSD-serotonin receptors have re- 
cently been demonstrated (Peroutka et al. 1981). 
It has been reported that DMT and LSD, while sharing 
similar hallucinogenic properties, show differences in the 
extent of dopaminergic and serotonergic involvement and 
activity (Glennon et al. 1980; Glennon and Rosecrans 1981; 
Nichols 1981). Prominent among LSD pharmacological and 
biochemical effects is a dual ability both to mimic and to 
block serotonin (5-HT) in the brain (Jacobs and Trulson 
1981) and also to interact with dopamiue (DA) and 5-HT 
receptors (Rosenfeld and Makman 1981). In addition, LSD 
has been shown to be a potent direct-acting DA agonist, 
whereas DMT is without effect (Cristoph et al. 1977; Von 
Hungen et al. 1975). Recently, binding studies have dem- 
onstrated that ~H-LSD can attach both to DA and 5-HT 
neurotransmitter sites, including spiroperidol-sensitive DA 
sites (Nielsen et al. 1980; Peroutka et al. 1981). The reported 
DA agonist activity is unique for LSD since other halluci- 
nogens, like DMT, mescaline, and psilocybin have not 
demonstrated similar dopaminergic agonist actions (Burt et 
al. 1976; Jacobs and Trulson 1979, 1981 ; Trulson et al. 1981). 
The synergistic effect of an increase in the dopaminergic 
activity combined with a decrease in serotonergic activity may 
be a major factor in hallucinogenic drug potency, with the DA 
agonist activity modulating the magnitude of drug response. 
Although DMT and LSD similarly decrease 5-HT turn- 
over, only LSD has been shown to increase brain norepineph- 
rine (NE) turnover and also alter the response of both 5-HT- 
and catecholamine-stimulated adenylate cyclase, whereas 
DMT alters only the catecholamine-stimulated response 
(Ahn and Makman 1979). Interestingly, morphine-like opio- 
ids have been shown to inhibit stimulated adenylate cyclase 
activity (Terenius and Wahlstrom 1978). 
The relationship of opioid peptides and synthetic analogs 
in psychological homeostasis is becoming increasingly impor- 
tant in view of their behavioral effects and high specificity of 
endorphin actions on brain functions (Frederickson et al. 
1980; Fuxe et al. 1980; Verebey 1981). The existence of 
multiple neurotransmitters and opioid receptors has been 
clearly documented, indicating important variations in the 
molecular mechanism of action (Morley 1980; Beddell et al. 
1980; Martin 1981). 
The data obtained in these investigations substantiate 
important interactions ofindole hallucinogens with opioids in 
the rat and strengthen the evidence for involvement of 
endogenous opioids in the pathogenesis of psychoses. The 
dramatic dose-dependent hallucinogen antagonistic effects of 
LY 127623 and FK 33-824 are especially significant and 
parallel previous findings involving interactions of morphine 
and methadone with DMT and LSD. These findings suggest 
that opioid agonists and related opioid-like peptides antago- 
nize the effects of DMT and LSD by a specific and selective 
opioid agonist action. It would be of interest to extend these 
findings using various behavioral paradigms to examine 
effects of chronic pretreatment of opioid agonists and related 
peptides, and possible effectiveness of opioid antagonists to 
reverse the antagonistic effects of opioid agonists on 
hallucinogen-induced behavior. 
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